RVX vs. MBX, EMH, PMN, DMT, HBP, IBT, ACST, AEZS, GSD, and LTY
Should you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Microbix Biosystems (MBX), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), Helix BioPharma (HBP), IBEX Technologies (IBT), Acasti Pharma (ACST), Aeterna Zentaris (AEZS), Devonian Health Group (GSD), and Liberty Biopharma (LTY). These companies are all part of the "biotechnology" industry.
Resverlogix vs.
Resverlogix (TSE:RVX) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
Resverlogix received 240 more outperform votes than Microbix Biosystems when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 70.71% of users gave Microbix Biosystems an outperform vote.
In the previous week, Microbix Biosystems had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for Resverlogix. Resverlogix's average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.26 indicating that Resverlogix is being referred to more favorably in the media.
0.4% of Microbix Biosystems shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Comparatively, 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Resverlogix has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Microbix Biosystems has higher revenue and earnings than Resverlogix. Resverlogix is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
Microbix Biosystems has a net margin of 21.73% compared to Resverlogix's net margin of 0.00%. Microbix Biosystems' return on equity of 20.04% beat Resverlogix's return on equity.
Summary
Microbix Biosystems beats Resverlogix on 9 of the 14 factors compared between the two stocks.
Get Resverlogix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Resverlogix Competitors List
Related Companies and Tools
This page (TSE:RVX) was last updated on 1/21/2025 by MarketBeat.com Staff
